Balance Sheet: Assets
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.

Biogen Inc., consolidated balance sheet: assets (quarterly data)

US$ in thousands

	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019	Dec 31, 2018	Sep 30, 2018	Jun 30, 2018	Mar 31, 2018	Dec 31, 2017	Sep 30, 2017	Jun 30, 2017	Mar 31, 2017
Cash and cash equivalents	3,675,600)	2,646,600)	1,749,300)	2,261,400)	1,541,800)	1,742,000)	1,217,500)	1,331,200)	2,224,800)	2,384,900)	2,591,300)	2,913,700)	2,343,900)	1,723,400)	2,243,200)	1,224,600)	2,386,700)	1,250,200)	4,108,000)	1,573,800)	1,548,100)	1,169,500)	924,000)
Marketable securities	1,235,500)	2,151,300)	2,002,400)	1,541,100)	1,413,300)	1,308,800)	1,320,000)	1,278,900)	1,355,000)	1,942,700)	1,269,100)	1,562,200)	2,093,500)	1,228,800)	1,665,800)	2,313,400)	2,041,700)	1,974,000)	1,808,000)	2,115,200)	1,960,200)	1,723,500)	1,956,200)
Accounts receivable, net	1,568,800)	1,567,600)	1,632,000)	1,549,400)	1,723,000)	1,688,000)	1,854,300)	1,913,800)	2,024,900)	2,133,600)	2,092,600)	1,880,500)	1,933,500)	1,959,600)	2,088,900)	1,958,500)	2,017,300)	1,951,000)	1,939,200)	1,787,000)	1,567,500)	1,630,200)	1,501,500)
Due from anti-CD20 therapeutic programs	415,400)	435,900)	389,400)	412,300)	400,000)	422,200)	369,800)	413,500)	527,200)	441,100)	511,600)	590,200)	582,300)	557,500)	527,100)	526,900)	508,400)	481,900)	553,500)	532,600)	518,000)	502,900)	324,500)
Inventory	1,375,000)	1,294,200)	1,215,400)	1,351,500)	1,347,900)	1,254,800)	1,171,800)	1,068,600)	1,027,700)	952,700)	858,800)	804,200)	751,800)	776,700)	770,200)	929,900)	916,600)	931,700)	890,800)	902,700)	1,007,200)	936,500)	921,600)
Assets held for sale	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	683,400)	682,000)	—)	—)	—)	—)	—)	—)	—)	—)
Other current assets	1,495,500)	1,645,300)	927,400)	740,800)	736,300)	767,900)	786,100)	881,100)	683,500)	638,800)	683,800)	631,000)	743,200)	980,400)	965,400)	687,600)	848,300)	843,300)	895,900)	962,000)	967,000)	1,146,100)	1,231,900)
Current assets	9,765,800)	9,740,900)	7,915,900)	7,856,500)	7,162,300)	7,183,700)	6,719,500)	6,887,100)	7,843,100)	8,493,800)	8,007,200)	8,381,800)	8,448,200)	7,909,800)	8,942,600)	7,640,900)	8,719,000)	7,432,100)	10,195,400)	7,873,300)	7,568,000)	7,108,700)	6,859,700)
Marketable securities	860,300)	1,102,900)	1,001,600)	892,000)	968,300)	915,100)	821,900)	772,100)	1,009,800)	922,800)	969,500)	1,408,100)	1,813,900)	1,309,300)	1,372,700)	1,375,900)	1,244,500)	1,160,200)	1,200,200)	3,057,300)	3,062,000)	2,632,700)	2,825,200)
Property, plant and equipment, net	3,266,400)	3,355,100)	3,372,800)	3,416,400)	3,410,700)	3,442,200)	3,438,300)	3,411,500)	3,359,900)	3,330,700)	3,281,600)	3,247,300)	3,138,100)	3,077,500)	3,013,800)	3,601,200)	3,538,900)	3,409,000)	3,334,700)	3,182,400)	2,995,900)	2,827,600)	2,610,900)
Operating lease assets	424,500)	321,100)	359,000)	375,400)	389,100)	402,500)	414,500)	433,300)	434,200)	436,200)	422,000)	427,000)	422,000)	434,400)	447,800)	—)	—)	—)	—)	—)	—)	—)	—)
Intangible assets, net	2,008,900)	2,075,300)	2,150,800)	2,221,300)	2,286,800)	2,385,000)	2,988,100)	3,084,300)	3,323,600)	3,383,800)	3,446,900)	3,527,400)	3,392,400)	3,681,300)	3,056,200)	3,120,000)	3,379,000)	3,661,300)	3,794,500)	3,879,600)	4,019,400)	4,051,300)	4,103,900)
Goodwill	5,741,200)	5,749,600)	5,758,000)	5,761,100)	5,760,500)	5,763,900)	5,763,100)	5,762,100)	5,755,700)	5,751,000)	5,752,000)	5,757,800)	5,746,100)	5,749,200)	5,639,700)	5,706,400)	5,440,100)	5,170,300)	4,907,800)	4,632,500)	4,127,500)	3,870,400)	3,611,700)
Deferred tax asset	1,174,500)	1,235,700)	1,288,800)	1,415,100)	1,810,400)	1,849,900)	1,286,300)	1,369,500)	1,372,900)	1,710,200)	3,109,400)	3,232,100)	3,284,500)	2,820,100)	2,074,400)	2,153,900)	2,160,900)	2,217,900)	2,277,400)	595,900)	—)	—)	—)
Investments and other assets	1,612,600)	1,500,800)	1,767,500)	1,939,500)	2,018,600)	2,528,100)	2,423,000)	2,899,000)	1,834,900)	1,483,300)	1,130,600)	1,252,800)	1,238,800)	1,306,000)	1,898,300)	1,690,600)	1,009,800)	902,100)	380,100)	431,600)	1,300,400)	1,268,300)	1,184,500)
Long-term assets	15,088,400)	15,340,500)	15,698,500)	16,020,800)	16,644,400)	17,286,700)	17,135,200)	17,731,800)	17,091,000)	17,018,000)	18,112,000)	18,852,500)	19,035,800)	18,377,800)	17,502,900)	17,648,000)	16,773,200)	16,520,800)	15,894,700)	15,779,300)	15,505,200)	14,650,300)	14,336,200)
Total assets	24,854,200)	25,081,400)	23,614,400)	23,877,300)	23,806,700)	24,470,400)	23,854,700)	24,618,900)	24,934,100)	25,511,800)	26,119,200)	27,234,300)	27,484,000)	26,287,600)	26,445,500)	25,288,900)	25,492,200)	23,952,900)	26,090,100)	23,652,600)	23,073,200)	21,759,000)	21,195,900)

The data reveals several noteworthy trends in the quarterly financial metrics.

Liquidity and Cash Position: Cash and cash equivalents experienced significant variability, peaking notably in early 2018 and fluctuating through late 2022, with the highest values observed at the end of 2022. Marketable securities displayed a decreasing pattern in the early periods of 2017-2018 but showed some recovery towards late 2019 and into 2022. The combination of cash and marketable securities indicates fluctuating but generally substantial liquid resources.
Receivables and Working Capital Assets: Accounts receivable showed a relatively steady range through the periods but generally declined slightly after 2019, suggesting moderately stable but possibly tighter credit management or lower sales volume. The amounts due from anti-CD20 therapeutic programs fluctuated with some declines after 2019, which may reflect changes in program delivery or billing cycles. Inventory levels increased over the years, especially after 2019, indicating accumulation or stockpiling possibly in anticipation of demand or production changes.
Other Current Assets and Assets Held for Sale: Other current assets initially declined from 2017 through 2018, then exhibited an increasing trend after 2021, including a large spike mid-2022, which could point to changes in prepaid expenses or other receivables. Assets held for sale appeared as a notable item only around 2019, implying some disposal or restructuring activity during that period.
Property, Plant, Equipment, and Intangible Assets: Property, plant, and equipment increased steadily until the end of 2018, reflecting ongoing capital investment, but showed slight decreases post-2019. Intangible assets consistently declined from 2017 through 2022, which may indicate amortization or asset impairments. Goodwill steadily increased until 2018 and remained fairly stable afterwards, suggesting no significant impairments or acquisitions affecting goodwill during recent periods.
Deferred Tax Assets and Long-Term Assets: Deferred tax assets rose sharply during 2017-2018 and peaked around 2019, followed by a steady decline through 2022, indicating utilization or revaluation of tax benefits. Long-term assets increased gradually until around 2019 before trending downward towards 2022, reflecting changes in capital investments and asset revaluations.
Total Assets: Total assets followed an increasing trend through 2018, peaking in 2019, but gradually declined afterward through late 2022, which may suggest asset sales, depreciation, or strategic realignment of the asset base.

Overall, the data indicates a period of growth in asset size up through 2019, followed by a consolidation or reduction phase. Liquidity fluctuated significantly but remained ample. Capital expenditures appeared to slow post-2018, with a marked reduction in intangible assets and deferred tax assets after 2019. Inventory trends suggest preparation for higher future demand or operational changes. The appearance of assets held for sale in 2019 signals potential restructuring initiatives within that timeframe. These patterns collectively illustrate a company adapting its asset base and liquidity management in response to evolving operational and market conditions.

Assets: Selected Items

Download chart

Current Assets: Selected Items

Download chart

Biogen Inc. (NASDAQ:BIIB)

Balance Sheet: Assets Quarterly Data

Assets: Selected Items

Current Assets: Selected Items

Balance Sheet: Assets
Quarterly Data